Page 131 - 南京医科大学自然版

第45卷第1期 沈 桐，胡 静，章海燕. 心肌肌球蛋白结合蛋白C在儿童肥厚型心肌病中的研究进展［J］.
2025年1月 南京医科大学学报（自然科学版），2025，45（1）：119-126 ·125 ·

Genet，2015，23（7）：922-928 proaches［J/OL］. FEBS J，2024［2024 ⁃ 05 ⁃ 05］. DOI：
［32］MAIN A，FULLER W，BAILLIE G S. Post⁃translational 10.1111/febs.17108
regulation of cardiac myosin binding protein⁃C：a graphi⁃ ［45］WITAYAVANITKUL N，AITMOU Y，KUSTER D W，et
cal review［J］. Cell Signal，2020，76：109788 al. Myocardial infarction⁃induced N⁃terminal fragment of
［33］SEVRIEVA I R，PONNAM S，YAN Z Q，et al. Phosphory⁃ cardiac myosin ⁃ binding protein C（cMyBP ⁃ C）impairs
lation⁃dependent interactions of myosin⁃binding protein C myofilament function in human myocardium［J］. J Biol
and troponin coordinate the myofilament response to pro⁃ Chem，2014，289（13）：8818-8827
tein kinase A［J］. J Biol Chem，2023，299（1）：102767 ［46］VYAS R，PANCHAL V，JAIN S，et al. Evaluating the effi⁃
［34］NAPIERSKI N C，GRANGER K，LANGLAIS P R，et al. cacy and safety of mavacamten in hypertrophic cardiomy⁃
A novel“cut and paste”method for in situ replacement of opathy：a systematic review and meta⁃analysis focusing on
cMyBP⁃C reveals a new role for cMyBP⁃C in the regula⁃ qualitative assessment ，biomarkers ，and cardiac imag⁃
tion of contractile oscillations［J］. Circ Res，2020，126 ing［J］. PLoS One，2024，19（4）：e0301704
（6）：737-749 ［47］SEBASTIAN S A，PADDA I，LEHR E J，et al. Aficamten：
［35］MICHIE K A，KWAN A H，TUNG C S，et al. A highly con⁃ a breakthrough therapy for symptomatic obstructive hyper⁃
served yet flexible linker is part of a polymorphic protein⁃ trophic cardiomyopathy［J］. Am J Cardiovasc Drugs，
binding domain in myosin ⁃ binding protein C［J］. Struc⁃ 2023，23（5）：519-532
ture，2016，24（11）：2000-2007 ［48］BISHEV D，FABARA S，LOSEKE I，et al. Efficacy and
［36］RASHDAN N A，SHRESTHA B，PATTILLO C B. S⁃gluta⁃ safety of mavacamten in the treatment of hypertrophic car⁃
thionylation，friend or foe in cardiovascular health and diomyopathy：a systematic review［J］. Heart Lung Circ，
disease［J］. Redox Biol，2020，37：101693 2023，32（9）：1049-1056
［37］ROSAS P C，SOLARO R J. Implications of S⁃glutathionyl⁃ ［49］BERTERO E，CHITI C，SCHIAVO M A，et al. Real⁃world
ation of sarcomere proteins in cardiac disorders，thera⁃ candidacy to mavacamten in a contemporary hypertrophic
pies，and diagnosis［J］. Front Cardiovasc Med，2022，9： obstructive cardiomyopathy population［J］. Eur J Heart
1060716 Fail，2024，26（1）：59-64
［38］SCHMID M，TOEPFER C N. Cardiac myosin super relax⁃ ［50］MARON M S，MASRI A，CHOUDHURY L，et al. Phase 2
ation（SRX）：a perspective on fundamental biology，hu⁃ study of aficamten in patients with obstructive hypertro⁃
man disease and therapeutics［J］. Biol Open，2021，10 phic cardiomyopathy［J］. J Am Coll Cardiol，2023，81（1）：
（2）：bio057646 34-45
［39］NAG S，TRIVEDI D V. To lie or not to lie：super⁃relaxing ［51］袁 叶，杨珍珍，于 博，等. 心肌肌球蛋白抑制剂治疗
with myosins［J］. Elife，2021，10：e63703 肥厚型心肌病的研究进展［J］. 中国药房，2023，34
［40］TOEPFER C N，WAKIMOTO H，GARFINKEL A C，et al. （21）：2684-2688
Hypertrophic cardiomyopathy mutations in MYBPC3 dys⁃ YUAN Y，YANG Z Z，YU B，et al. Advances in the treat⁃
regulate myosin［J］. Sci Transl Med，2019，11（476）： ment of hypertrophic cardiomyopathy with cardiac myosin
eaat1199 inhibitors［J］. China Pharmacy，2023，34（21）：2684-2688
［41］WANG Z W，MA K，ZHU Y B，et al. Innovation in surgi⁃ ［52］SPERTUS J A，FINE J T，ELLIOTT P，et al. Mavacamten
cal treatment of hypertrophic obstructive cardiomyopathy for treatment of symptomatic obstructive hypertrophic car⁃
in children［J/OL］. Cardiol Young，2024［2024⁃04⁃11］. diomyopathy（EXPLORER⁃HCM）：health status analysis
DOI：10.1017/S104795112400057X of a randomised，double⁃blind，placebo⁃controlled，phase
［42］WILDER T，RYBA D M，WIECZOREK D F，et al. N⁃acety⁃ 3 trial［J］. Lancet，2021，397（10293）：2467-2475
lcysteine reverses diastolic dysfunction and hypertrophy ［53］KEAM S J. Mavacamten：first approval［J］. Drugs，2022，
in familial hypertrophic cardiomyopathy［J］. Am J Physiol 82（10）：1127-1135
Heart Circ Physiol，2015，309（10）：H1720-H1730 ［54］MASRI A，SHERRID M V，ABRAHAM T P，et al. Efficacy
［43］ZHOU X X，JEONG E M，LIU H，et al. Circulating S⁃glu⁃ and safety of aficamten in symptomatic nonobstructive
tathionylated cMyBP⁃C as a biomarker for cardiac diastol⁃ hypertrophic cardiomyopathy：results from the RED⁃
ic dysfunction［J］. J Am Heart Assoc，2022，11（11）： WOOD ⁃ HCM trial，cohort 4［J/OL］. J Card Fail，2024
e025295 ［2024⁃05⁃15］. DOI：10.1016/j.cardfail.2024.02.020
［44］STASTNA M. Post⁃translational modifications of proteins ［55］KINNEAR C，SAID A，MENG G L，et al. Myosin inhibitor
in cardiovascular diseases examined by proteomic ap⁃ reverses hypertrophic cardiomyopathy in genotypically